VPAC1 receptor binding site: contribution of photoaffinity labeling approach.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Neuropeptides

• Publication date

  2010-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.npep.2009.11.008PMID 20031208
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery

  2009cited by this paper
• Molecular and conformational determinants of pituitary adenylate cyclase-activating polypeptide (PACAP) for activation of the PAC1 receptor.

  2009cited by this paper
• Passing the baton in class B GPCRs: peptide hormone activation via helix induction?

  2009cited by this paper
• VPAC and PAC receptors: From ligands to function.

  2009cited by this paper
• Crystal structure of opsin in its G-protein-interacting conformation

  2008cited by this paper
• Structure of a β1-adrenergic G-protein-coupled receptor

  2008cited by this paper
• Class-B GPCR activation: is ligand helix-capping the key?

  2008cited by this paper
• Molecular recognition of parathyroid hormone by its G protein-coupled receptor

  2008cited by this paper
• Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain*

  2008cited by this paper
• The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist

  2008cited by this paper
• The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics.

  2008cited by this paper
• The N-Terminal Parts of VIP and Antagonist PG97–269 Physically Interact with Different Regions of the Human VPAC1 Receptor

  2008cited by this paper
• Spatial Approximation between Secretin Residue Five and the Third Extracellular Loop of Its Receptor Provides New Insight into the Molecular Basis of Natural Agonist Binding

  2008cited by this paper
• New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond.

  2008cited by this paper
• Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications

  2008cited by this paper
• Vasoactive Intestinal Peptide–Mediated Th17 Differentiation

  2008cited by this paper
• Molecular Recognition of Corticotropin-releasing Factor by Its G-protein-coupled Receptor CRFR1*

  2008cited by this paper
• Is cortical bone hip? What determines cortical bone properties?

  2007cited by this paper
• Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS

  2007cited by this paper
• High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.

  2007cited by this paper
• Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor

  2007cited by this paper
• Distinct Structural and Functional Roles of Conserved Residues in the First Extracellular Domain of Receptors for Corticotropin-releasing Factor and Related G-protein-coupled Receptors*

  2007cited by this paper
• Neuroprotection: a comparative view of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide.

  2007cited by this paper
• Fluorescence Resonance Energy Transfer Analysis of Secretin Docking to Its Receptor

  2007cited by this paper
• Incretin-based therapies: mimetics versus protease inhibitors.

  2007cited by this paper
• Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology.

  2007cited by this paper
• From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP

  2007cited by this paper
• High-Resolution Crystal Structure of an Engineered Human β2-Adrenergic G Protein–Coupled Receptor

  2007cited by this paper
• Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP.

  2006cited by this paper
• Peptide Agonist Docking in the N-terminal Ectodomain of a Class II G Protein-coupled Receptor, the VPAC1 Receptor

  2006cited by this paper
• Glucagon-like peptide-2: update of the recent clinical trials.

  2006cited by this paper
• Constitutive Formation of Oligomeric Complexes between Family B G Protein-Coupled Vasoactive Intestinal Polypeptide and Secretin Receptors

  2006cited by this paper
• Drug Insight: existing and emerging therapies for osteoporosis

  2006cited by this paper
• Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors.

  2005cited by this paper
• NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor.

  2004influential reference
• Diffuse Pharmacophoric Domains of Vasoactive Intestinal Peptide (VIP) and Further Insights into the Interaction of VIP with the N-terminal Ectodomain of Human VPAC1 Receptor by Photoaffinity Labeling with [Bpa6]-VIP*

  2004cited by this paper
• Corticotropin-releasing factor antagonists: recent advances and exciting prospects for the treatment of human diseases.

  2004cited by this paper
• The Significance of Vasoactive Intestinal Peptide in Immunomodulation

  2004cited by this paper
• Photoaffinity Labeling Demonstrates Physical Contact between Vasoactive Intestinal Peptide and the N-terminal Ectodomain of the Human VPAC1 Receptor*

  2003cited by this paper
• Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.

  2003cited by this paper
• Novel Receptor Partners and Function of Receptor Activity-modifying Proteins*

  2003cited by this paper
• Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor

  2002cited by this paper
• Identification of secretin, vasoactive intestinal peptide and glucagon binding sites: from chimaeric receptors to point mutations.

  2001cited by this paper
• Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease

  2001cited by this paper
• Two Basic Residues of the h-VPAC1 Receptor Second Transmembrane Helix Are Essential for Ligand Binding and Signal Transduction*

  2001cited by this paper
• VIP: A very important protein in arthritis

  2001cited by this paper
• Packing-induced Conformational and Functional Changes in the Subunits of α-Crystallin*

  2000cited by this paper
• Crystal structure of rhodopsin: A G protein-coupled receptor.

  2000cited by this paper
• Packing-induced conformational and functional changes in the subunits of alpha -crystallin.

  2000cited by this paper
• Identification of Key Residues for Interaction of Vasoactive Intestinal Peptide with Human VPAC1 and VPAC2Receptors and Development of a Highly Selective VPAC1Receptor Agonist

  2000cited by this paper
• Immunology of VIP: a review and therapeutical perspectives.

  2000cited by this paper
• In vitro properties of a high affinity selective antagonist of the VIP1 receptor.

  1997cited by this paper
• Rational design, synthesis, and biological evaluation of novel growth hormone releasing factor analogues

  1995cited by this paper
• Vasoactive intestinal polypeptide (VIP): current status.

  1984cited by this paper

• PACTS-Assisted Thermal Proteome Profiling for Use in Identifying Peptide-Interacting Proteins.

  2022cites this paper
• VIP Receptors

  2021cites this paper
• In-silico studies on conformational stability of flagellin–receptor complexes

  2020influential citation
• Design and biological assessment of membrane-tethering neuroprotective peptides derived from the pituitary adenylate cyclase-activating polypeptide type 1 receptor.

  2019cites this paper
• Glucagon-Like Peptide-2 and the Enteric Nervous System Are Components of Cell-Cell Communication Pathway Regulating Intestinal Na+/Glucose Co-transport

  2018cites this paper
• The Pharmacophoric Determinants of PACAP

  2016cites this paper
• Strategies for studying the ligand binding site of GPCRs: photoaffinity labeling of the VPAC1 receptor, a prototype of class B GPCRs.

  2013cites this paper
• VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins

  2012cites this paper
• Conformational switches in the VPAC1 receptor

  2012cites this paper
• RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells.

  2012cites this paper
• The family B1 GPCR: structural aspects and interaction with accessory proteins.

  2012cites this paper
• Themed Section : Secretin Family ( Class B ) G Protein-Coupled Receptors – from Molecular to Clinical Perspectives

  2012influential citation
• The VPAC1 receptor: structure and function of a class B GPCR prototype

  2012influential citation
• Spatial proximity between the VPAC1 receptor and the amino terminus of agonist and antagonist peptides reveals distinct sites of interaction

  2012cites this paper
• Guide to Receptors and Channels (GRAC), 5th edition

  2011cites this paper
• Characterization of Intestinal and Pancreatic Dysfunction in VPAC1-Null Mutant Mouse

  2011cites this paper
• Strategies to convert PACAP from a hypophysiotropic neurohormone into a neuroprotective drug.

  2011cites this paper
• Identification by photoaffinity labeling of the extracellular N-terminal domain of PAC1 receptor as the major binding site for PACAP.

  2011cites this paper
• Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis

  2011cites this paper
• A furin/MMP-14 proteolytic cascade generates Vasculostatin-40 from extracellular BAI1: Implications for angiogenesis and tumorigenesis

  2011cites this paper
• A Conformationally Constrained Peptidomimetic Binds to the Extracellular Region of HER2 Protein

  2010cites this paper